Safety of routine childhood vaccinations: An epidemiological review

被引:19
作者
Chen R.T. [1 ]
Mootrey G. [1 ]
DeStefano F. [1 ]
机构
[1] Vaccine Safety/Devt. Branch, National Immunisation Program, Centers for Dis. Ctrl./Prevention, Atlanta
来源
Paediatric Drugs | 2000年 / 2卷 / 4期
关键词
Chronic Fatigue Syndrome; Aseptic Meningitis; Vaccine Safety; Oral Poliovirus Vaccine; Vaccine Adverse Event Reporting System;
D O I
10.2165/00128072-200002040-00004
中图分类号
学科分类号
摘要
Immunisations have been one of the most cost-effective public health interventions in human history. Despite remarkable progress, several challenges face immunisation programs worldwide. Paradoxically, despite vaccines' clear effectiveness in reducing risks of diseases that were previously widely prevalent and caused substantial morbidity and mortality, current vaccination policies have become increasingly controversial due to concerns about vaccine safety. Vaccines, like other pharmaceutical products, are not entirely risk-free. While most known adverse effects are minor and self-limited, some vaccines have been associated with very rare but serious adverse effects. Because such rare effects are often not evident until vaccines come into widespread use, ongoing surveillance programs to monitor vaccine safety are needed. Such monitoring will be essential if the public is to accept the increasing number of new vaccines made possible by biotechnology. The interpretation of data from vaccine safety research is complex and is associated with some uncertainty. Effectively communicating this uncertainty and continuing to improve understanding of rare risks and risk factors are essential for 'mature' immunisation programs to maintain public confidence in immunisations.
引用
收藏
页码:273 / 290
页数:17
相关论文
共 158 条
[81]  
Niu M., Davis D., Ellenberg S., Recombinant hepatitis B vaccination of neonates and infants: Emerging safety data from the Vaccine Adverse Event Reporting System (VAERS), Pediatr Infect Dis J, 15, 9, pp. 771-776, (1996)
[82]  
Niu M., Rhodes P., Salive M., Et al., Comparative safety of two recombinant hepatitis B vaccines in children: Data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD), J Clin Epidemiol, 51, 6, pp. 503-510, (1998)
[83]  
Dobson S., Scheifele D., Bell A., Assessment of a universal, school-based hepatitis B vaccination program, JAMA, 274, 15, pp. 1209-1213, (1995)
[84]  
Pope J., Stevens A., Howson W., Et al., The development of rheumatoid arthritis after recombinant hepatitis B vaccination, J Rheum, 25, pp. 1687-1693, (1998)
[85]  
Bracci M., Zoppini A., Polyarthritis associated with hepatitis B vaccination, Br J Rheumatol, 36, 2, pp. 300-301, (1997)
[86]  
McMahon B.J., Helminiak C., Wainwright R.B., Et al., Frequency of adverse reactions to hepatitis B vaccine in 43,618 persons, Am J Med, 92, pp. 254-256, (1992)
[87]  
Malawista S.E., Infectious arthritis, pp. 1520-1521, (1992)
[88]  
Gross K., Combe C., Kruger K., Et al., Arthritis after hepatitis B vaccination, Scand J Rhematol, 24, pp. 50-52, (1995)
[89]  
Hachulla E., Houvenagel E., Mingul A., Et al., Reactive arthritis after hepatitis B vaccination: Case report questions cross reacting antigenic determinants between infecting agents and HLA-B27, J Rhematol, 17, pp. 1250-1251, (1990)
[90]  
Biasi D., DeSandre G., Bambara L.M., Et al., A new case of reactive arthritis after hepatitis B vaccination, Clin Exp Rheumatol, 11, (1993)